We provide the latest news
from the world of economics and financeLooking at the universe of stocks we cover at Dividend Channel, on 8/16/24, Amgen Inc (Symbol: AMGN), Royalty Pharma plc (Symbol: RPRX), and Arbor Realty Trust Inc (Symbol: ABR) will all trade ex-dividend for their respective upcoming dividends. Amgen Inc will pay its quarterly dividend of $2.25 on 9/6/24, Royalty Pharma plc will pay its quarterly dividend of $0.21 on 9/13/24, and Arbor Realty Trust Inc will pay its quarterly dividend of $0.43 on 8/30/24. As a percentage of AMGN's recent stock price of $323.45, this dividend works out to approximately 0.70%, so look for shares of Amgen Inc to trade 0.70% lower — all else being equal — when AMGN shares open for trading on 8/16/24. Similarly, investors should look for RPRX to open 0.78% lower in price and for ABR to open 3.18% lower, all else being equal.
Below are dividend history charts for AMGN, RPRX, and ABR, showing historical dividends prior to the most recent ones declared.
Amgen Inc (Symbol: AMGN):
Royalty Pharma plc (Symbol: RPRX):
Arbor Realty Trust Inc (Symbol: ABR):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.78% for Amgen Inc, 3.13% for Royalty Pharma plc, and 12.73% for Arbor Realty Trust Inc.
In Wednesday trading, Amgen Inc shares are currently up about 1.1%, Royalty Pharma plc shares are up about 1.6%, and Arbor Realty Trust Inc shares are up about 1.1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Top Ten Hedge Funds Holding APSG
Institutional Holders of PWB
CSAL Price Target
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.